2023
Does Symptom-Onset Treatment With Sertraline Improve Functional Impairment for Individuals With Premenstrual Dysphoric Disorder?
Yonkers K, Altemus M, Gilstad-Hayden K, Kornstein S, Gueorguieva R. Does Symptom-Onset Treatment With Sertraline Improve Functional Impairment for Individuals With Premenstrual Dysphoric Disorder? Journal Of Clinical Psychopharmacology 2023, 43: 320-325. PMID: 37212651, PMCID: PMC10313784, DOI: 10.1097/jcp.0000000000001700.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderFunctional impairmentSymptom onsetPMDD symptomsDysphoric disorderAnger/irritabilityDaily treatmentActive treatmentFunctional outcomeClinical trialsFunctional improvementSecondary analysisCausal mediation analysisSertralineSeverity of problemsImpairmentNonsignificant direct effectDaily ratingsPlaceboTreatmentFace validitySymptomsIrritabilityDisordersSignificant indirect effect
2004
HPA axis activation in major depression and response to fluoxetine: a pilot study
Young E, Altemus M, Lopez J, Kocsis J, Schatzberg A, deBattista C, Zubieta J. HPA axis activation in major depression and response to fluoxetine: a pilot study. Psychoneuroendocrinology 2004, 29: 1198-1204. PMID: 15219644, DOI: 10.1016/j.psyneuen.2004.02.002.Peer-Reviewed Original ResearchConceptsHPA axis activationMetyrapone challengeOnset of treatmentAxis activationMajor depressionHPA axisHamilton Depression Rating Scale ratingsOpen-label treatmentHPA axis dysregulationAdrenal axis activationPremenopausal womenLabel treatmentACTH levelsHormonal contraceptivesMedical illnessACTH secretionAxis dysregulationNormal womenDepressed patientsFluoxetine respondersDepressed womenNormal subjectsAxis IGreater severityFluoxetine
1999
Open trial of flutamide for treatment of obsessive-compulsive disorder.
Altemus M, Greenberg B, Keuler D, Jacobson K, Murphy D. Open trial of flutamide for treatment of obsessive-compulsive disorder. The Journal Of Clinical Psychiatry 1999, 60: 442-5. PMID: 10453797, DOI: 10.4088/jcp.v60n0704.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderAndrogen receptorEstrogen receptorClassical intracellular androgen receptorsOCD symptomsPrimary outcome measureFuture treatment trialsIntracellular androgen receptorHamilton Rating ScaleGonadal steroid hormonesAndrogen receptor antagonistYale-Brown Obsessive Compulsive ScaleEffect of treatmentBeck Anxiety InventoryLack of responseObsessive Compulsive ScaleOpen trialTreatment trialsReceptor antagonistGonadal steroidsOutcome measuresCompetitive antagonistEstrogen activityFlutamideSteroid hormones
1997
Effect of prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a preliminary study
Greenberg B, George M, Martin J, Benjamin J, Schlaepfer T, Altemus M, Wassermann E, Post R, Murphy D. Effect of prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a preliminary study. American Journal Of Psychiatry 1997, 154: 867-869. PMID: 9167520, DOI: 10.1176/ajp.154.6.867.Peer-Reviewed Original Research
1994
Changes in Cerebrospinal Fluid Neurochemistry During Treatment of Obsessive-compulsive Disorder With Clomipramine
Altemus M, Swedo S, Leonard H, Richter D, Rubinow D, Potter W, Rapoport J. Changes in Cerebrospinal Fluid Neurochemistry During Treatment of Obsessive-compulsive Disorder With Clomipramine. JAMA Psychiatry 1994, 51: 794-803. PMID: 7524463, DOI: 10.1001/archpsyc.1994.03950100042004.Peer-Reviewed Original ResearchConceptsCorticotropin-releasing hormoneLong-term treatmentObsessive-compulsive disorderCSF levelsHomovanillic acidCSF monoamine metabolite levelsCentral administrationCerebrospinal fluid levelsSignificant decreaseCSF homovanillic acidMonoamine metabolite levelsCerebrospinal fluid neurochemistryCSF oxytocin levelsOpposite behavioral effectsPharmacologic treatmentSomatostatin levelsMonoamine metabolitesPathophysiologic processesFluid levelsBehavioral effectsOxytocin levelsClomipramine hydrochlorideMetabolite levelsDisordersVasopressin